- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00051974
Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
February 7, 2008 updated by: Millennium Pharmaceuticals, Inc.
A Randomized, Multicenter, Open-Label, Phase 2 Study of VELCADE Alone or VELCADE Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
The purpose of this study is to evaluate how tumors in patients with non-small cell lung cancer respond to treatment with VELCADE alone versus VELCADE given with docetaxel and also to see what effects (good and bad) it has on you and your cancer.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
In this study, patients with non-small cell lung cancer that is no longer responding to standard medical treatment with another anti-cancer drug will be randomly chosen to receive treatment with VELCADE alone or VELCADE in combination with docetaxel.
Patients have almost equal chance of getting into either of the two treatment arms listed above.
Study Type
Interventional
Enrollment
155
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- U of Alambama at Birmingham Comprehensive Cancer Center
-
-
California
-
Los Angeles, California, United States, 90048
- Cedars-Sinai Comprehensive Cancer Center
-
Los Angeles, California, United States, 90095
- UCLA Medical Center Thoracic Malignancy
-
-
Colorado
-
Aurora, Colorado, United States, 80010
- University of Colorado Health Sciences Center
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Yale University School of Medicine
-
-
Florida
-
Gainesville, Florida, United States, 32610
- Univeristy of Florida Shands Cancer Center
-
Miami, Florida, United States, 33136
- Sylvester Comprehensive Cancer Center
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Winship Cancer Institute
-
Decatur, Georgia, United States, 30033
- Atlanta VAMC
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Mass. General Hospital Hem/Onc. Associates
-
-
Missouri
-
Kansas City, Missouri, United States, 64154
- DBA Kansas City Cancer Centers
-
St. Louis, Missouri, United States, 63110
- St. Louis University Health Sciences Center
-
St. Louis, Missouri, United States, 63110
- Washington University, Barnard Cancer Center
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28203
- Carolinas Hematology-Oncology Associates
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Kimmel Cancer Center at Jefferson
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University-Clinical Trials Center
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas MD Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Hunstman Cancer Institute-University of Utah
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin Comprehensive Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
- Inoperable, locally advanced (Stage IIIB) or metastatic (Stage IV) NSCLC that has been histologically or cytologically confirmed.
- No more than 1 prior chemotherapy regimen.
- 18 years of age or older.
- Measurable or evaluable disease.
- KPS ≥70%.
- Life expectancy greater than 3 months.
- Female patient is either post-menopausal, surgically sterilized, or willing to use an acceptable method of birth control for the duration of the study.
- Male patient agrees to use an acceptable method of birth control for the duration of the study.
- Provide written informed consent before any study-related procedure not part of normal medical care is conducted.
- Willing and able to comply with the protocol requirements.
Exclusion Criteria
Peripheral neuropathy of Grade 2 or greater intensity, as defined by the NCI Common Toxicity Criteria (CTC):
- Grade 2: Objective sensory loss or paresthesia (including tingling), interfering with function, but not interfering with activities of daily living (ADLs).
- Grade 3: Sensory loss or paresthesia interfering with ADLs.
- Grade 4: Permanent sensory loss that interferes with function.
- Previous treatment with VELCADE.
- Previous treatment with docetaxel (prior treatment with paclitaxel will be allowed).
- Chemotherapy within 4 weeks prior to enrollment.
- Radiation therapy within 4 weeks prior to enrollment.
- Monoclonal antibodies within 6 weeks prior to enrollment.
- Any major surgery within 4 weeks prior to enrollment.
Inadequate organ function at the Screening visit as defined by the following laboratory values:
- Platelet count ≤100,000 x 109/L
- Hemoglobin ≤8.0 g/dL
- Absolute neutrophil count (ANC) ≤1.5 x 109/L
- Aspartate transaminase (AST) ≥3 x the upper limit of the normal range (ULN)
- Alanine transaminase (ALT) ≥3 times ULN
- Creatinine ≥1.8 mg/dL
- Total bilirubin ≥2 times ULN
- Myocardial infarction within 6 months prior to enrollment or has New York Hospital Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant.
- No history of brain metastases or central nervous system disease.
- Active systemic infection requiring treatment.
- Treatment for a cancer other than NSCLC within 5 years prior to enrollment, with the exception of basal cell carcinoma or cervical cancer in situ.
- History of allergic reaction attributable to compounds containing boron or mannitol.
- Known to be human immunodeficiency virus (HIV)-positive. Patients assessed by the investigator to be at risk for HIV infection should be tested in accordance with local regulations.
- Known to be hepatitis B surface antigen-positive or has known active hepatitis C infection. Patients assessed by the investigator to be at risk for hepatitis B or C infection should be tested in accordance with local regulations.
- Poorly controlled hypertension, diabetes mellitus, or another serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
- Pregnant or breast-feeding female patient. Confirmation that the patient is not pregnant must be established by a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test result obtained during the Screening period. Pregnancy testing is not required for post-menopausal or surgically sterilized women.
- Currently enrolled in another clinical research study or has received an investigational agent for any reason within 4 weeks of enrollment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2002
Primary Completion (Actual)
September 1, 2004
Study Registration Dates
First Submitted
January 21, 2003
First Submitted That Met QC Criteria
January 21, 2003
First Posted (Estimate)
January 22, 2003
Study Record Updates
Last Update Posted (Estimate)
February 11, 2008
Last Update Submitted That Met QC Criteria
February 7, 2008
Last Verified
February 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- M34102-048
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
-
Memorial Sloan Kettering Cancer CenterAstraZenecaRecruitingNSCLC | Lung Cancer | Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | PD-L1 Gene Mutation | Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage IIUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)WithdrawnStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
Clinical Trials on VELCADE™ (bortezomib) for Injection (formerly PS-341)
-
Millennium Pharmaceuticals, Inc.TerminatedAdvanced Non-Small Cell Lung Cancer | Other Solid Tumors
-
Millennium Pharmaceuticals, Inc.CompletedColorectal CarcinomaUnited States
-
Baylor College of MedicineMillennium Pharmaceuticals, Inc.CompletedProstate NeoplasmsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedLeukemia | Chronic Myeloproliferative DisordersUnited States
-
M.D. Anderson Cancer CenterMillennium Pharmaceuticals, Inc.CompletedLeukemiaUnited States
-
M.D. Anderson Cancer CenterMillennium Pharmaceuticals, Inc.CompletedLymphoma, B-CellUnited States
-
M.D. Anderson Cancer CenterMillennium Pharmaceuticals, Inc.CompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal CancerUnited States
-
M.D. Anderson Cancer CenterCompletedMultiple MyelomaUnited States
-
Rasim GucalpMillennium Pharmaceuticals, Inc.TerminatedNon-small Cell Lung CancerUnited States
-
Beijing Chao Yang HospitalEnrolling by invitationMultiple Myeloma | BortezomibChina